Systemischer Lupus erythematodes, Systemische Sklerose

Psenak, O; Fortbildungsseminar für Turnusärzte SALK; 09.01.2018; Salzburg. 2018.

Xeljanz Kasuistik

Psenak, O; Pfizer Jahresbuch. 2018.

News from ASCO 2018

Balic, M; Dedic, N; De Mattos-Arruda, L; Gampenrieder, S BREAST CARE. 2018; 13(4): 298-302.

Non-Hodgkin lymphoma risk in adults living with HIV across five continents The AIDS-defining Cancer Project Working Group of leDEA and COHERE in EuroCoord

Rohner, E; Butikofer, L; Schmidlin, K; Sengayi, M; Maskew, M; Giddy, J; Moore, RD; Goedert, JJ; Gill, MJ; Silverberg, MJ; Patel, P; Castilho, J; Hoy, J; Sohn, A; Bani-Sadr, F; Taylor, N; Paparizos, V; Le Moing, V; Bonnet, F; Verbon, A; Vehreschild, JJ; Post, FA; Sabin, C; Mocroft, A; Dronda, F; Obel, N; Grabar, S; Spagnuolo, V; Antinori, A; Quiros-Rol-Dan, E; Mussini, C; Miro, JM; Meyer, L; Hasse, B; Konopnicki, D; Roca, B; Boue, F; Barger, D; Raben, D; Clifford, GM; Franceschi, S; Brockmeyer, N; Egger, M; Bohlius, J AIDS. 2018; 32(18): 2777-2786.

Investigating epigenetic effects of activation-induced deaminase in chronic lymphocytic leukemia.

Schubert, M; Hackl, H; Gassner, FJ; Greil, R; Geisberger, R; PLoS One. 2018; 13(12): e0208753

Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia-results of the AMLSG 11-08 trial

Paschka, P; Schlenk, RF; Weber, D; Benner, A; Bullinger, L; Heuser, M; Gaidzik, VI; Thol, F; Agrawal, M; Teleanu, V; Lubbert, M; Fiedler, W; Radsak, M; Krauter, J; Horst, HA; Greil, R; Mayer, K; Kundgen, A; Martens, U; Heil, G; Salih, HR; Hertenstein, B; Schwanen, C; Wulf, G; Lange, E; Pfreundschuh, M; Ringhoffer, M; Girschikofsky, M; Heinicke, T; Kraemer, D; Gohring, G; Ganser, A; Dohner, K; Dohner, H LEUKEMIA. 2018; 32(7): 1621-1630.

Casein kinase 1 is a therapeutic target in chronic lymphocytic leukemia.

Janovska, P; Verner, J; Kohoutek, J; Bryjova, L; Gregorova, M; Dzimkova, M; Skabrahova, H; Radaszkiewicz, T; Ovesna, P; Blanarova, OV; Nemcova, T; Hoferova, Z; Vasickova, K; Smyckova, L; Egle, A; Pavlova, S; Poppova, L; Plevova, K; Pospisilova, S; Bryja, V BLOOD. 2018; 131(11): 1206-1218.

Correction to: Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study.

Egle, A; Steurer, M; Melchardt, T; Weiss, L; Gassner, FJ; Zaborsky, N; Geisberger, R; Catakovic, K; Hartmann, TN; Pleyer, L; Voskova, D; Thaler, J; Lang, A; Girschikofsky, M; Petzer, A; Greil, R; Ann Hematol. 2018; 97(9):1745

Intensified preoperative chemoradiation by adding oxaliplatin in locally advanced, primary operable (cT3NxM0) rectal cancer : Impact on long-term outcome. Results of the phase II TAKO 05/ABCSG R‑02 trial.

Kogler, P; DeVries, AF; Eisterer, W; Thaler, J; Sölkner, L; Öfner, D; Strahlenther Onkol. 2018; 194(1): 41-49.

Rac GTPases in Hematological Malignancies

Durand-Onayli, V; Haslauer, T; Harzschel, A; Hartmann, TN INT J MOL SCI. 2018; 19(12): 4041